BioCentury on BioBusiness,
Emerging Company Profile
InfiMed: Hydrogels for sustained release
Monday, January 11, 1999
While chronic dosing might be a nice feature for a new chemical entity whose manufacturer is looking for long-term sales potential, less frequent administration would be preferred by patients and might expand the market opportunity. Less frequent dosing also may decrease side effects and increase efficacy of certain biologics by maintaining more consistent levels of drug in the patient's system.
InfiMed Therapeutics Inc. intends to provide manufacturers of protein and peptide drugs with the less frequent dosing option. Its technologies for sustained release drug delivery use polyethylene glycol (PEG)-based hydrogels that can be administered as intramuscular or subcutaneous depot injections. Release of drug is controlled by degradation of the hydrogel in the body - the timing of which can be controlled by altering the characteristics of the hydrogel.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]